Skip to main content

Pandorum Technologies

ApplicationBengaluru, IndiaFounded 2011· One of 702 Application companies tracked by AMPulse

Bioprinting pioneer creating lab-grown human tissues for drug discovery and regenerative medicine

CEO / Founder
Tuhin Bhowmick
Team Size
51-200
Stage
Active
Total Funding
$68.5M
Latest Round
Series B
Key Investors
Protons Corporate, Ashish Kacholia, Indian Angel Network, Galentic Pharma, Everest Finance Investment, Acebright Pharma, Noblevast Advisory, Avinya Fund, Burman Family

Technology & Products

Key Products

Engineered liver models, corneal models, Kuragenx "Liquid Cornea" therapy, proprietary bioprinting platform

Technical position · AMPulse analysis

Proprietary bioprinting platform for high-precision tissue engineering

Differentiation

Value Proposition

Lab-grown human liver and corneal tissues for high-precision drug testing and regenerative medicine

How They Differentiate

Focus on Indian market and corneal blindness treatment

Market & Competition

Target Customers

Pharmaceutical companies, research institutions, hospitals

Industry Verticals

Pharmaceuticals, Biotechnology, Healthcare, Research

Competitors

Organovo, Aspect Biosystems, CELLINK

Growth & Milestones

Growth Metrics

Pre-revenue in FY24, ₹401Cr valuation, multiple pharmaceutical partnerships

Major Milestones

2011: Founded, 2016: Created India's first 3D printed liver tissue, 2024: $11M Pre-Series B, 2026: $18M Series B led by Protons Corporate

Notable Customers

Pharmaceutical companies using liver/corneal models for drug testing

https://pandorum.com

Recent coverage of Pandorum Technologies

AM patents

AM-relevant patents linked to this company.

Patents
4
Granted
0
Families
2

Leading domains: application (4), process (4), material (3)

Filings by year: 2023: 1 · 2019: 3

  1. BIO-INK FORMULATIONS, BIO-PRINTED CORNEAL LENTICULE, AND APPLICATIONS THEREOF4003225 · EP
  2. BIO-INK FORMULATIONS, BIO-PRINTED CORNEAL LENTICULE, AND APPLICATIONS THEREOF20220273844 · US
  3. A LENTICULE, METHOD OF PREPARATION AND IMPLEMENTATIONS THEREOF2025120669 · WO
  4. HYALURONIC ACID AND GELATIN-CONTAINING FORMULATIONS20220218873 · US

Funding rounds

  • Series B$18M2026-02Lead: Protons Corporate · Source: Web
  • Pre-Series B$11M2024-03Source: Web
  • Seed$1M2016-01Source: Web

Why this company matters

AMPulse analysis, not a company disclosure

Pandorum Technologies occupies a distinctive position as India's first bioprinting company to create lab-grown human tissues, addressing gaps in drug testing accuracy and corneal blindness treatment. Founded in 2011, the company differentiates itself from global peers like Organovo and CELLINK by focusing on the Indian market and developing a cure for corneal blindness through its Kuragenx Liquid Cornea therapy.

The company's core technology is a proprietary bioprinting platform designed for high-precision tissue engineering. Its key products include engineered liver and corneal models for pharmaceutical drug testing, alongside the Kuragenx therapy for regenerative medicine. These models aim to reduce reliance on animal testing and improve preclinical prediction of human drug responses.

Pandorum targets pharmaceutical companies, research institutions, and hospitals, with multiple pharmaceutical partnerships in place. The company achieved a notable milestone in 2016 by creating India's first 3D printed human liver tissue. As of FY24, it remains pre-revenue but carries a valuation of ₹401 crore, supported by investors including Protons Corporate, Ashish Kacholia, and the Indian Angel Network.

The company's strategic moat lies in its first-mover advantage in India's bioprinting sector and its focus on corneal blindness, a large unmet need. However, it faces competitive risk from established global bioprinting firms and must demonstrate commercial traction to justify its valuation. The recent INR 85 crore Series B led by Protons Corporate signals continued investor confidence in its path to revenue.